The total Non-small cell lung cancer incident cases in the 7MM were observed to be 484,726 cases in the year 2017.
Non-Small cell lung cancer market is anticipated to increase in the 7MM from USD 9,730 million in 2017 by 2030.
Key players such as AstraZeneca, Bristol Myers Squibb, AbbVie, Roche, Merck, Novartis, Pfizer, Takeda, Eli Lilly and Company, Johnson & Johnson, Sanofi, GSK, along with others are driving the non-small cell lung cancer market forward.
For more details visit:
https://www.delveinsight.com/blog/non-small-cell-lung-cancer-market-2/